ARGENX SE (ARGX)
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
argenx SE
NASDAQ:ARGXHealthcare · Biotechnology
-0.55%$892.87
AH$893.30+0.05%vs close
Mkt Cap$56.15B
Float59.12M
O/S62.89M
Vol
$ Vol
RVOL
Inst Own45.0%
SI2.3%
Earnings
Dilution
Financials Summary
Revenue$4.15B
Net Income$1.29B
Total Assets$8.68B
Free Cash Flow$844.3M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$83.49M
Total Equity$7.32B
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in ARGX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$8.68B
Liabilities$1.36B
Accounts Receivable$1.66B
Accounts Payable$1.27B
Inventory$473.53M
PP&E (Net)$48.25M
Goodwill$0
Intangible Assets$272.1M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Revenue | $4.15B | $2.19B | $1.23B | $410.75M | $1.08B | $41.24M | $78.46M | $24.57M | $43.69M | $15.47M | $7.49M | $4.57M | $3.7M | $2.18M | $1.46M |
| YoY Growth | 89.6% | 78.6% | 198.6% | -61.9% | 2513.3% | -47.4% | 219.3% | -43.8% | 182.3% | 106.5% | 64.1% | 23.5% | 69.4% | 49.7% | - |
| Cost of Revenue | $450.67M | $227.29M | $117.83M | $29.43M | $580.52M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.02M | $0 | $0 |
| Gross Profit | $3.7B | $1.96B | $1.11B | $381.31M | $497.28M | $41.24M | $78.46M | $24.57M | $43.69M | $15.47M | $7.49M | $4.57M | $2.68M | $2.18M | $1.46M |
| Gross Margin | 89.1% | 89.6% | 90.4% | 92.8% | 46.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 72.4% | 100.0% | 100.0% |
| Research and Development | $1.36B | $983.42M | $859.49M | $663.37M | $580.52M | $370.49M | $220.77M | $95.64M | $62.07M | $33.19M | $22.56M | $15.37M | $12.91M | $14.63M | $6.25M |
| Selling, General, and Administrative | $1.36B | $1.06B | $709.54M | $469.92M | $305.52M | $170.55M | $72.15M | $26.33M | $14.93M | $7.37M | $5.38M | $4.21M | $2.94M | $2.67M | $2.46M |
| Other | -$75.91M | -$54.16M | -$35.5M | -$31.63M | -$40.02M | -$22.18M | -$15.56M | -$3.77M | -$5.81M | -$2.56M | -$3.39M | -$1.97M | -$3.56M | -$1.83M | -$2.54M |
| Total Operating Expenses | $2.65B | $1.98B | $1.53B | $1.1B | $846.02M | $518.86M | $277.35M | $118.2M | $71.2M | $38M | $24.55M | $17.63M | $12.3M | $15.48M | $6.18M |
| Operating Income (EBIT) | $1.05B | -$21.65M | -$425.05M | -$720.34M | -$348.75M | -$477.62M | -$198.89M | -$93.63M | -$27.51M | -$22.52M | -$17.06M | -$13.06M | -$8.81M | -$13.29M | -$4.72M |
| Operating Margin | 25.4% | -1.0% | -34.7% | -175.4% | -32.4% | -1158.1% | -253.5% | -381.0% | -63.0% | -145.6% | -227.7% | -286.1% | -238.2% | -608.9% | -323.6% |
| Interest Expense | $4.08M | $2.22M | $904K | $2.19M | $1.1M | $404K | $139K | $0 | $0 | $0 | $0 | $4K | $6K | $3K | $1K |
| Interest Income | $163.09M | $138.5M | $92.96M | $24.74M | $3.48M | $5.15M | $8.8M | $4.23M | $198K | $64K | $83K | $167K | $257K | $460K | $205K |
| Other Income (Expense) | $223.99M | $106.83M | $120.55M | -$8.97M | -$51M | -$127.73M | $22.97M | $18.3M | -$5.46M | $44K | $320K | $522K | $2.37M | $467K | $227K |
| Income Before Tax (EBT) | $1.28B | $85.18M | -$304.5M | -$729.31M | -$399.74M | -$605.35M | -$175.92M | -$75.32M | -$32.97M | -$22.48M | -$16.74M | -$12.54M | -$8.47M | -$12.83M | -$4.49M |
| Income Tax Expense | -$13.43M | -$747.86M | -$9.44M | -$19.72M | $8.52M | $3.1M | $5.29M | $908K | $716K | $0 | $0 | $0 | -$303K | $0 | $0 |
| Net Income | $1.29B | $833.04M | -$295.05M | -$709.59M | -$408.26M | -$608.46M | -$181.21M | -$76.23M | -$33.68M | -$22.48M | -$16.74M | -$12.54M | -$8.47M | -$12.83M | -$4.49M |
| Net Income Margin | 31.1% | 38.0% | -24.1% | -172.8% | -37.9% | -1475.3% | -231.0% | -310.2% | -77.1% | -145.3% | -223.4% | -274.6% | -229.0% | -587.5% | -308.0% |
| Supplementary Data | |||||||||||||||
| EPS | 21.14 | 13.92 | -5.16 | -13.05 | -7.99 | -13.40 | -4.69 | -2.12 | -1.37 | -1.19 | -1.06 | -0.80 | -0.54 | -0.82 | -0.29 |
| Diluted EPS | 19.63 | 12.78 | -5.16 | -13.05 | -7.99 | -13.40 | -4.69 | -2.12 | -1.37 | -1.20 | -1.06 | -0.80 | -0.54 | -0.82 | -0.29 |
| Weighted Average OS | 61.30M | 59.86M | 57.17M | 54.38M | 51.08M | 45.41M | 38.62M | 35.98M | 24.61M | 18.82M | 15.73M | 15.71M | 15.71M | 15.71M | 15.71M |
| EBITDA | $1.31B | $105.17M | -$192.28M | -$622.78M | -$392.78M | -$601.03M | -$173.35M | -$93.06M | -$32.45M | -$22.17M | -$16.53M | -$12.38M | -$8.29M | -$12.56M | -$4.2M |
| EBITDA Margin | 31.6% | 4.8% | -15.7% | -151.6% | -36.4% | -1457.3% | -220.9% | -378.7% | -74.3% | -143.3% | -220.6% | -271.0% | -224.3% | -575.4% | -288.2% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
| Assets | ||||||||||||||||
| Current Assets | ||||||||||||||||
| Cash and Cash Equivalents | $3.49B | $1.5B | $2.05B | $800.74M | $1.33B | $1.22B | $372.16M | $321.48M | $228.98M | $94.55M | $38.83M | $39.13M | $31.37M | $20.41M | $30.52M | $10.5M |
| Short-Term Investments | $948.75M | $1.88B | $1.13B | $1.39B | $1B | $779.65M | $1.13B | $283.53M | $202.64M | $7.18M | $6.81M | $28.93M | $690K | $1.39M | $0 | $0 |
| Cash and Short-Term Investments | $4.44B | $3.38B | $3.18B | $2.19B | $2.34B | $2B | $1.5B | $645.81M | $431.62M | $101.73M | $46.28M | $68.06M | $32.06M | $21.8M | $30.52M | $10.5M |
| Accounts Receivable | $1.66B | $909.1M | $499.27M | $277.27M | $38.22M | $7.44M | $22.61M | $214K | $3.08M | $1.12M | $719K | $1.59M | $1.52M | $95K | $613K | $1.39M |
| Inventory | $473.53M | $407.23M | $310.55M | $228.35M | $109.08M | $25.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $0 | $7.9M | $4.7M | $2.55M | $2.05M | $764K | -$12.39M | $1K | $477K | $375K | $0 |
| Total Current Assets | $6.9B | $4.88B | $4.12B | $2.77B | $2.54B | $2.06B | $1.54B | $654.82M | $440.06M | $107.06M | $48.26M | $57.38M | $33.73M | $22.48M | $31.57M | $11.89M |
| Long-Term Assets | ||||||||||||||||
| Property, Plant & Equipment Net | $48.25M | $43.52M | $22.68M | $16.23M | $15.84M | $11.58M | $9.18M | $943K | $811K | $806K | $272K | $155K | $166K | $231K | $356K | $328K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $272.1M | $181.44M | $125.23M | $174.9M | $171.68M | $167.34M | $45.12M | $64K | $16K | $18K | $8K | $9K | $0 | $0 | $16K | $41K |
| Long-Term Investments | $89.59M | $49.7M | $47.16M | $40.48M | $53.17M | $6.31M | $2.92M | $1K | $1K | $1K | $1K | $1K | $1K | $1K | $0 | $0 |
| Deferred Tax Assets | $1.3B | $924.3M | $97.21M | $79.22M | $32.19M | $15.04M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $77.8M | $120.46M | $126.45M | $49.23M | $34.42M | $22.14M | $10.33M | $5.87M | $4.1M | $3.36M | $1.71M | $970K | $642K | $218K | $0 | $0 |
| Total Long-Term Assets | $1.78B | $1.32B | $418.72M | $360.06M | $307.3M | $222.41M | $67.54M | $6.88M | $4.92M | $4.18M | $2M | $1.13M | $809K | $451K | $372K | $369K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $8.68B | $6.2B | $4.54B | $3.13B | $2.85B | $2.28B | $1.61B | $661.7M | $444.98M | $111.24M | $50.25M | $58.51M | $34.54M | $22.93M | $31.94M | $12.26M |
| Liabilities | ||||||||||||||||
| Current Liabilities | ||||||||||||||||
| Accounts Payable | $1.27B | $342.23M | $245.56M | $188.72M | $208.85M | $206.32M | $10.51M | $6.87M | $5.28M | $4.63M | $2.94M | $4.08M | $2.89M | $2.5M | $888K | $1.69M |
| Short-Term Debt | $10.83M | $6.53M | $4.65M | $3.42M | $3.51M | $3.48M | $2.22M | $0 | $0 | $0 | $0 | $0 | $0 | $1.69M | $1.68M | $0 |
| Current Income Tax Payable | $0 | $13.39M | $4.33M | $3.18M | $4.32M | $3.5M | $386K | $941K | $716K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $46.33M | $136.28M | $23.21M | $14.48M | $35.52M | $4.5M | $4.18M | $628K | $568K | $0 | $339K |
| Other Current Liabilities | -$212.34M | $156.95M | $73.35M | $22.62M | $828K | $0 | $144K | $30K | $1.92M | -$8.64M | $450K | $254K | $73K | $664K | $697K | -$272 |
| Total Current Liabilities | $1.32B | $669.92M | $422.99M | $302.28M | $301.24M | $328.49M | $179.7M | $45.82M | $29.41M | $34M | $9.43M | $10.25M | $4.57M | $6.28M | $4.04M | $2.03M |
| Long-Term Liabilities | ||||||||||||||||
| Long-Term Debt | $36.33M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $269.04M | $244.94M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $5.16M | $8.41M | $6.44M | $1.49M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | -$33.23M | $1.8M | $1.45M | $870K | $417K | $156K | $72K | $7K | $1.75M | $10.59M | $0 | $0 | -$1K | $0 | $0 | $0 |
| Total Long-Term Liabilities | $39.42M | $34.32M | $21.96M | $18.29M | $14.81M | $276.86M | $250.11M | $8K | $1.75M | $10.59M | $0 | $0 | -$1K | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.36B | $704.24M | $444.95M | $320.56M | $316.05M | $605.36M | $429.81M | $45.83M | $31.16M | $44.59M | $9.43M | $8.43M | $4.57M | $6.28M | $4.04M | $2.03M |
| Stockholders' Equity | ||||||||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $7.35M | $6.98M | $6.39M | $6.64M | $6.23M | $5.74M | $5.21M | $4.12M | $3.86M | $2.12M | $1.73M | $1.91M | $643K | $448K | $439K | $248K |
| Retained Earnings | -$279.77M | -$1.57B | -$2.4B | -$2.11B | -$1.4B | -$991.93M | -$383.48M | -$194.01M | -$120.65M | -$76.24M | -$55.89M | -$43.54M | -$35.2M | -$25.6M | -$12.52M | -$8.41M |
| Comprehensive Income & Other | $73.59M | $66.71M | $72.07M | $71.72M | $465.41M | $321.21M | $53.04M | $35.4M | $14.11M | $7.88M | $5.08M | $2.89M | $1.97M | $1.56M | $540K | $297K |
| Other Stockholders' Equity | $7.6B | $7.06B | $6.5B | $4.92B | $3.93B | $2.66B | $1.56B | $805.77M | $530.61M | $140.78M | $94.92M | $102.53M | $64.53M | $41.81M | $39.98M | $18.39M |
| Total Equity | $7.32B | $5.5B | $4.1B | $2.81B | $2.53B | $1.67B | $1.18B | $615.87M | $413.81M | $66.65M | $40.76M | $60.9M | $29.97M | $16.65M | $27.9M | $10.23M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $8.68B | $6.2B | $4.54B | $3.13B | $2.85B | $2.28B | $1.61B | $661.7M | $444.98M | $111.24M | $50.19M | $69.33M | $34.54M | $22.93M | $31.94M | $12.26M |
| Supplementary Data | ||||||||||||||||
| Total Debt | $83.49M | $39.05M | $20M | $12.43M | $11.46M | $9.66M | $7.32M | $0 | $0 | $0 | $0 | $0 | $0 | $1.69M | $1.68M | $0 |
| Net Debt | -$3.41B | -$1.46B | -$2.03B | -$788.31M | -$1.32B | -$1.21B | -$364.84M | -$321.48M | -$228.98M | -$94.55M | -$38.83M | -$39.13M | -$31.37M | -$18.71M | -$28.83M | -$10.5M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Operating Activities | |||||||||||||||
| Net Income | $1.05B | $833.04M | -$425.05M | -$720.34M | -$348.75M | -$477.62M | -$198.89M | -$93.63M | -$27.51M | -$22.52M | -$17.06M | -$13.06M | -$8.6M | -$13.29M | -$4.72M |
| Depreciation & Amortization | $28.1M | $17.53M | $111.31M | $104.34M | $5.87M | $3.92M | $2.42M | $564K | $522K | $351K | $214K | $161K | $167K | $262K | $288K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $248.08M | $235.18M | $232.97M | $157.03M | $179.37M | $96.93M | $44.24M | $21.94M | $5.12M | $3M | $2.48M | $1.16M | $338K | $1.01M | $258K |
| Changes in Working Capital: | |||||||||||||||
| Accounts Receivable | -$804.81M | -$422.36M | -$185.69M | -$222.26M | -$31.63M | $21.96M | -$25.71M | -$50K | -$146K | -$646K | -$712K | -$859K | -$1.34M | $220K | $337K |
| Inventory | -$99.26M | -$95.83M | -$83.03M | -$119.28M | -$83.88M | -$23.85M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $614.22M | $245.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Working Capital | -$134.09M | -$52.31M | -$40.17M | -$34.51M | -$225.44M | -$26.49M | $335.74M | $10.25M | -$21.87M | $30.97M | -$117K | $6.24M | $322K | $718K | -$148K |
| Total Working Capital Change | -$423.94M | -$324.6M | -$308.89M | -$375.93M | -$340.95M | -$28.38M | $310.03M | $10.2M | -$22.02M | $30.32M | -$829K | $5.38M | -$1.02M | $938K | $189K |
| Other Non-Cash Items | -$55.57M | -$843.89M | -$30.67M | -$27.91M | -$102.35M | $6.68M | -$6.17M | -$667K | $42K | $732 | -$287 | -$4K | -$5K | -$4K | -$883 |
| Net Cash from Operating | $850.49M | -$82.75M | -$420.33M | -$862.81M | -$606.81M | -$398.46M | $151.63M | -$61.59M | -$43.84M | $11.15M | -$15.19M | -$6.37M | -$9.12M | -$11.09M | -$3.98M |
| Investing Activities | |||||||||||||||
| Capital Expenditures | -$112.03M | -$1.8M | -$812K | -$837K | -$3.62M | -$1.07M | -$1.8M | -$712K | -$414K | -$883K | -$300K | -$212K | -$90K | -$115K | -$307K |
| Acquisitions | $0 | -$7M | -$13M | -$2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$1.46B | -$2.18B | -$1.27B | -$1.69B | -$228.24M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $2.4B | $1.43B | $1.54B | $1.33B | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $45.15M | $49.75M | -$89.84M | -$115.21M | $345.76M | -$831.47M | -$122.31M | -$194M | $35K | $18.68M | -$28.17M | $1.02M | $461K | $203K |
| Net Cash from Investing | $823.88M | -$717.59M | $308.21M | -$461.18M | -$347.07M | $344.69M | -$833.27M | -$123.02M | -$194.41M | -$848K | $18.38M | -$28.38M | $927K | $346K | -$104K |
| Financing Activities | |||||||||||||||
| Debt Repaid | $4.11M | $7.64M | $3.8M | $4.17M | $3.85M | $2.55M | $1.51M | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $279.24M | $308.72M | $1.2B | $760.95M | $1.12B | $813.19M | $755.64M | $292.52M | $393.14M | $48.35M | $260K | $50.7M | $18.38M | $0 | $24.88M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$41.4M | -$21.32M | $143.8M | $86.97M | $438K | $22.37M | -$20.4M | -$12.64M | -$26.8M | -$1.43M | $0 | -$4.8M | $0 | $0 | -$322K |
| Net Cash from Financing | $233.73M | $279.76M | $1.34B | $843.76M | $1.12B | $833M | $733.73M | $279.88M | $366.35M | $46.93M | $260K | $45.89M | $18.38M | $0 | $24.55M |
| Forex Effect | $83.26M | -$28.33M | $23.49M | -$53.7M | -$49.59M | $65.41M | -$1.72M | $7.87M | -$6.96M | -$33K | $198K | $359K | -$115K | $8K | $22K |
| Net Change in Cash | $1.99B | -$548.91M | $1.25B | -$533.94M | $117.87M | $844.64M | $50.37M | $103.15M | $121.13M | $57.2M | $3.65M | $11.5M | $10.07M | -$10.73M | $20.49M |
| Supplementary Data | |||||||||||||||
| Operating Cash Flow | $850.49M | -$82.75M | -$420.33M | -$862.81M | -$606.81M | -$398.46M | $151.63M | -$61.59M | -$43.84M | $11.15M | -$15.19M | -$6.37M | -$9.12M | -$11.09M | -$3.98M |
| Capital Expenditure | -$6.18M | -$68.3M | -$43.81M | -$103.82M | -$121.43M | -$5.14M | -$46.73M | -$782K | -$421K | -$906K | -$305K | -$225K | -$90K | -$115K | -$308K |
| Free Cash Flow | $844.3M | -$151.05M | -$464.14M | -$966.63M | -$728.25M | -$403.6M | $104.89M | -$62.37M | -$44.27M | $10.24M | -$15.5M | -$6.59M | -$9.21M | -$11.2M | -$4.29M |
| Cash at Beginning | $1.5B | $2.05B | $800.74M | $1.33B | $1.22B | $372.16M | $321.79M | $218.33M | $107.85M | $37.35M | $35.18M | $27.63M | $21.31M | $31.14M | $10.03M |
| Cash at End | $3.49B | $1.5B | $2.05B | $800.74M | $1.33B | $1.22B | $372.16M | $321.48M | $228.98M | $94.55M | $38.83M | $39.13M | $31.37M | $20.41M | $30.52M |